{"schema_version":"secwatch.filing_event.v1","accession":"0001588978-23-000012","form_type":"8-K","ticker":"PRCT","cik":"0001588978","company_name":"PROCEPT BioRobotics Corp","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.551031+00:00","generated_at":"2026-06-16T08:58:43.227158+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PROCEPT BioRobotics Q1 revenue up 72% to $24.4M; raises FY2023 revenue guidance to $128M","bullets":["Total revenue $24.4M (+72% YoY); U.S. handpiece/consumables $11.8M (+165% YoY).","Net loss $28.5M vs $17.2M; Adjusted EBITDA loss $23.9M vs $13.5M.","FY2023 revenue guidance raised to $128M (from $125M); gross margin guidance ~54% (from ~53%).","United Healthcare positive coverage policy effective June 1, 2023; national sales contract with largest U.S. IDN signed April 1.","U.S. install base 192 AquaBeam systems; monthly utilization per account 6.3, up 14% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001588978-23-000012","json":"https://secwatch.observer/filing/0001588978-23-000012.json","markdown":"https://secwatch.observer/filing/0001588978-23-000012.md","text":"https://secwatch.observer/filing/0001588978-23-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1588978/000158897823000012/0001588978-23-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1588978/000158897823000012/prct-20230427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T08:58:43.227158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35ec456e6fd423882141a54eb206a3553586e612","claim":"PROCEPT BioRobotics Corp reported full year 2023 results: revenue $128 million. Guidance raised.","evidence_excerpt":"The Company projects revenue for the full year 2023 to be $128 million, which represents 71% growth over the Company’s prior year revenue.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1588978/000158897823000012/0001588978-23-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$128 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"ca0946a015e24fa5bda30eefd6c235a2088231ac","claim":"PROCEPT BioRobotics Corp reported the quarter ended March 31, 2023 results: revenue Total revenue of $24.4 million for the first quarter of 2023, net income Net loss was $28.5 million for the first quarter of 2023.","evidence_excerpt":"PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1588978/000158897823000012/0001588978-23-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"Total revenue of $24.4 million for the first quarter of 2023"},{"label":"Net income","value":"Net loss was $28.5 million for the first quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}